Boston Scientific Says It Will Pause Hypertension Trial
This article is for subscribers only.
Boston Scientific Corp. won’t begin a study of its hypertension treatment until it can analyze a failed effort by Medtronic Inc. and review its approach with U.S. regulators, Chief Executive Officer Michael Mahoney said.
While Boston Scientific has Food and Drug Administration backing to start a pivotal trial of its Vessix technology, the company is waiting to see whether the failure of Medtronic’s product in a study last week stemmed from the device or the clinical trial design, or whether the entire approach is invalid.